Intestinal-specific activatable Myb initiates colon tumorigenesis in mice
- Author(s)
- Malaterre, J; Pereira, L; Putoczki, T; Millen, R; Paquet-Fifield, S; Germann, M; Liu, J; Cheasley, D; Sampurno, S; Stacker, SA; Achen, MG; Ward, RL; Waring, P; Mantamadiotis, T; Ernst, M; Ramsay, RG;
- Journal Title
- Oncogene
- Publication Type
- Journal Article in press
- Abstract
- Transcription factor Myb is overexpressed in most colorectal cancers (CRC). Patients with CRC expressing the highest Myb are more likely to relapse. We previously showed that mono-allelic loss of Myb in an Adenomatous polyposis coli (APC)-driven CRC mouse model (ApcMin/+) significantly improves survival. Here we directly investigated the association of Myb with poor prognosis and how Myb co-operates with tumor suppressor genes (TSGs) (Apc) and cell cycle regulator, p27. Here we generated the first intestinal-specific, inducible transgenic model; a MybER transgene encoding a tamoxifen-inducible fusion protein between Myb and the estrogen receptor-alpha ligand-binding domain driven by the intestinal-specific promoter, Gpa33. This was to mimic human CRC with constitutive Myb activity in a highly tractable mouse model. We confirmed that the transgene was faithfully expressed and inducible in intestinal stem cells (ISCs) before embarking on carcinogenesis studies. Activation of the MybER did not change colon homeostasis unless one p27 allele was lost. We then established that MybER activation during CRC initiation using a pro-carcinogen treatment, azoxymethane (AOM), augmented most measured aspects of ISC gene expression and function and accelerated tumorigenesis in mice. CRC-associated symptoms of patients including intestinal bleeding and anaemia were faithfully mimicked in AOM-treated MybER transgenic mice and implicated hypoxia and vessel leakage identifying an additional pathogenic role for Myb. Collectively, the results suggest that Myb expands the ISC pool within which CRC is initiated while co-operating with TSG loss. Myb further exacerbates CRC pathology partly explaining why high MYB is a predictor of worse patient outcome.Oncogene advance online publication, 24 August 2015; doi:10.1038/onc.2015.305.
- Publisher
- NPG
- Research Division(s)
- Inflammation
- PubMed ID
- 26300002
- Publisher's Version
- https://doi.org/10.1038/onc.2015.305
- Open Access at Publisher's Site
http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2015305a.html- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2016-02-29 12:23:47
Last Modified: 2016-03-01 04:57:47